Christopher Smith is the Director and Chief Executive Officer at NeoGenomics, Inc., a leading cancer genetics diagnostic company. With a strong background in the life sciences and healthcare industries, Smith has been instrumental in driving NeoGenomics' growth and innovation. Prior to joining NeoGenomics, he held various leadership positions at renowned organizations, including Quest Diagnostics and LabCorp, where he honed his expertise in laboratory services, diagnostics, and strategic management. As CEO of NeoGenomics, Smith has been at the forefront of the company's mission to improve patient outcomes through advanced cancer testing and information services. Under his leadership, NeoGenomics has expanded its portfolio of diagnostic tests, including next-generation sequencing and molecular diagnostics, to provide comprehensive insights for personalized cancer treatment. Smith's strategic vision has also led to the company's geographic expansion, with the establishment of multiple state-of-the-art laboratories across the United States, enabling faster turnaround times and increased accessibility to cutting-edge cancer diagnostics. Christopher Smith's achievements at NeoGenomics have been recognized by the industry, with the company being named one of the fastest-growing companies in the healthcare sector. His commitment to innovation and patient-centric care has solidified NeoGenomics' position as a leader in cancer diagnostics. As Director and CEO, Smith continues to guide the company's growth strategy, foster collaborations with leading research institutions, and drive the development of novel diagnostic solutions that empower oncologists and patients in their fight against cancer.